Thomas B. Neff Sells 18,899 Shares of FibroGen Inc. (FGEN) Stock
FibroGen Inc. (NASDAQ:FGEN) CEO Thomas B. Neff sold 18,899 shares of the business’s stock in a transaction on Monday, October 3rd. The stock was sold at an average price of $20.55, for a total value of $388,374.45. Following the transaction, the chief executive officer now owns 3,370,103 shares in the company, valued at $69,255,616.65. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Shares of FibroGen Inc. (NASDAQ:FGEN) opened at 20.05 on Friday. The firm’s market cap is $1.26 billion. FibroGen Inc. has a 12 month low of $14.38 and a 12 month high of $31.90. The firm’s 50-day moving average price is $19.65 and its 200-day moving average price is $18.69.
FibroGen (NASDAQ:FGEN) last released its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported $0.35 EPS for the quarter, missing analysts’ consensus estimates of $0.36 by $0.01. FibroGen had a negative return on equity of 48.66% and a negative net margin of 61.90%. Analysts expect that FibroGen Inc. will post ($1.25) earnings per share for the current year.
Separately, Credit Suisse Group AG restated a “buy” rating on shares of FibroGen in a research note on Tuesday, July 12th.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in FGEN. Acadian Asset Management LLC purchased a new position in FibroGen during the second quarter worth approximately $106,000. Acrospire Investment Management LLC boosted its stake in shares of FibroGen by 240.2% in the second quarter. Acrospire Investment Management LLC now owns 6,657 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 4,700 shares during the last quarter. Teacher Retirement System of Texas boosted its stake in shares of FibroGen by 15.7% in the second quarter. Teacher Retirement System of Texas now owns 6,891 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 937 shares during the last quarter. Quantbot Technologies LP bought a new stake in shares of FibroGen during the second quarter valued at about $164,000. Finally, Fox Run Management L.L.C. bought a new stake in shares of FibroGen during the second quarter valued at about $176,000. Institutional investors own 49.82% of the company’s stock.
FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.
Receive News & Stock Ratings for FibroGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc. and related stocks with our FREE daily email newsletter.